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Purpose: Patients with persistent or recurrent
neutropenic fevers at risk of invasive fungal disease
(IFD) are treated empirically with antifungal therapy
(AFT). Early treatment using a diagnostic-driven (DD)
strategy may reduce clinical and economic burdens.
We compared costs and outcomes of both strategies
from a UK perspective.
Methods: An empirical strategy with conventional
amphotericin B deoxycholate (C-AmB), liposomal
amphotericin B (L-AmB), or caspofungin was com-
pared with a DD strategy (initiated based on positive
ELISA results for galactomannan antigen) and/or
positive results for Aspergillus species on polymerase
chain reaction assay) using C-AmB, voriconazole, or
L-AmB in a decision-analytic model. Rates of IFD
incidence, overall mortality, and IFD-related mortality
in adults expected to be neutropenic for Z10 days
were obtained. The empirical strategy was assumed to
identify 30% of IFD and targeted AFT to improve
survival by a hazard ratio of 0.589. AFT-speciﬁc
adverse events were obtained from a summary of
product characteristics. Resource use was obtained,
and costs were estimated by using standard UK cost-
ing sources. All costs are presented in 2012 British
pounds sterling.
Findings: Total costs were 32% lower for the DD
strategy (£1561.29) versus the empirical strategyJune 2015(£2301.93) due to a reduced incidence of adverse
events and decreased use of AFT. Administration of
AFT was reduced by 41% (DD strategy, 74 of 1000;
empirical strategy, 125 of 1000), with similar survival
rates.
Implications: This study suggests that a DD strategy is
likely to be cost-saving versus empirical treatment for
immunocompromised patients with persistent or recurrent
neutropenic fevers. (Clin Ther. 2015;37:1317–1328)
& 2015 The Authors. Published by Elsevier HS
Journals, Inc.
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beneﬁt, fungal infection.INTRODUCTION
Invasive fungal disease (IFD) is associated with high
mortality rates in severely immunocompromised
patients, such as those undergoing intensive chemo-
therapy or stem cell transplantation.1 IFD results in
increased hospital and intensive care unit costs, with1317
Clinical Therapeuticspharmacy expenditures (including antifungal treat-
ment) the main cost driver.2
Because IFD is life-threatening, empirical therapy is
commonly used in at-risk patients.3 With this strategy,
patients are treated for suspected IFD when they
present with persistent or recurrent neutropenic
fevers that are unresponsive to broad-spectrum anti-
bacterial therapy for 72 to 96 hours. Conventional
amphotericin B deoxycholate (C-AmB), liposomal
amphotericin B (L-AmB), and caspofungin are cur-
rently the only antifungal agents licensed for empirical
treatment in the setting of persistent or recurrent
neutropenic fevers. Empirical treatment can be costly,
however,4–6 with the potential for overtreatment of
nonfungal fever, resulting in increased toxicity and
treatment-related costs.7
Early use of diagnostic assays in a diagnostic-driven
(DD) therapy strategy is 1 way to potentially identify
patients with invasive aspergillosis (IA) more accu-
rately and, consequently, to better select treatments
for these patients. In addition, earlier diagnosis and
targeted therapy may reduce costs and improve out-
comes by eliminating unnecessary toxic treatment.
Several studies have helped us to better understand
the clinical impact of a DD strategy compared with a
standard empirical strategy.7–12 However, these studies
do not highlight the economic impact of a DD therapy
strategy.
In the present study, we examined the impact on
costs and outcomes that may occur in neutropenic
patients with a suspected IFD caused by Aspergillus
species when treated by using either a typical empirical
strategy with antifungal therapy administered to all
patients or an early-treatment DD strategy with more
targeted antifungal therapy.
PATIENTS AND METHODS
A decision-analytic model was developed to examine
the costs and outcomes associated with the standard
empirical strategy, in which all patients with persistent
or recurrent neutropenic fevers were treated with
C-AmB, L-AmB, or caspofungin, compared with a
DD strategy, in which selected patients were treated
with C-AmB, L-AmB, or voriconazole. Antifungal
agents were chosen based on the indications listed in
the summaries of product characteristics as well as
expert feedback.
The model was developed from a UK perspective
and included a time horizon of 5 months.13 All costs1318are presented in 2012 British pounds sterling. Costs
and outcomes were not discounted because the time
horizon was o1 year.
Population
Patients were assumed to be aged Z18 years with
hematologic malignancies, undergoing chemotherapy
or autologous/allogeneic hematopoietic stem cell
transplantation, and expected to be severely neutro-
penic (neutrophil count o0.5  109 cells/L) for
Z10 days.7–12 Patients could not have had a diagnosis
of proven or probable IFD or have received treatment
with an investigational antifungal agent in the previous
6 months.
Comparators
DD Strategy
Patients began antifungal therapy when they were
suspected of having an IFD based on characteristic
lesions on computed tomography scan, Aspergillus
species colonization, and/or positive ELISA results for
galactomannan antigen (GM) and/or positive results
for Aspergillus species on polymerase chain reaction
(PCR) assay. Patients were treated with C-AmB,
L-AmB, or voriconazole.
Empirical Strategy
Patients began antifungal therapy when they had
persistent or recurrent neutropenic fevers that failed to
defervesce despite broad-spectrum antibacterial therapy
for 72 to 96 hours, with no IFD identiﬁed. Patients were
treated with C-AmB, L-AmB, or caspofungin.
Model Structure
The decision model (Figures 1A1C) was designed
as a standard decision tree, with chance nodes
representing the probability of occurrence of each
event and decision nodes representing decision
points. Patients at risk for IFD, such as those with
IA, were entered into the model and were assigned to
each strategy as soon as they became neutropenic. At
baseline for treatment of initial neutropenic fevers,
patients underwent a standard diagnostic evaluation,
which included blood cultures, urine cultures, body
site–speciﬁc microbiologic cultures, serum bio-
chemistry, and hematology studies. After the standard
diagnostic evaluation, initial empirical broad-spectrum
antibacterial therapy was initiated. Thereafter, other
monitoring and microbiologic tests were performed, asVolume 37 Number 6
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Figure 1. Model structure showing (A) overall structure, (B) diagnostic-driven (DD) strategy decision tree,
and (C) empirical strategy decision tree with point estimates. Chance nodes (circles) represent the
probability of occurrence of each event, and decision nodes (squares) represent decision points.
IFD ¼ invasive fungal disease.
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Clinical Therapeuticsclinically appropriate, during the episode of neutro-
penic fevers.
Once persistent or recurrent neutropenic fevers
were established, a decision was made to manage
them according to the patient’s assigned strategy.
Patients in the DD strategy group were treated
similarly to patients in the empirical strategy group
except the former received antifungal prophylaxis
with ﬂuconazole, and additional health care resources
(eg, GM-ELISA and PCR testing) were used to
diagnose IFD. It was assumed that the DD strategy
and the empirical strategy were initiated at the
same time.
In the DD strategy (Figure 1B), an IFD was
diagnosed on the basis of clinical and biomarker
ﬁndings. As a result, patients with a probable or
possible diagnosis of IA were treated with appropriate
antifungal agents. Patients without a probable or
possible diagnosis were not treated with antifungal
agents. However, the model structure allowed patients
without a conﬁrmed diagnosis of IFD to receive
antifungal treatment at the discretion of the clinician
while awaiting the outcome of other investigations if an
IFD was strongly suspected on clinical grounds. After
treatment or no treatment, patients either survived or
died (based on the epidemiologic and clinical data
obtained from the published literature).
In the empirical strategy (Figure 1C), patients were
treated with antifungal agents on the basis of
persistent or recurrent fevers, regardless of whether
the IFD was conﬁrmed to exist. A portion of patients
may have had proven or probable IFD, another
portion of patients may deﬁnitely not have had an
IFD, and the remainder of patients may have had an
IFD but never had its existence conﬁrmed. After
treatment or no treatment, patients either survived
or died (based on the epidemiologic and clinical data
taken from the published literature).
Model Inputs
Incidence
To estimate the costs and outcomes associated with
each treatment strategy, the incidence of IFD within a
particular clinical setting was required. Within the
model, the incidence of IFD was assumed to be 10.9%
(95% CI, 9–13), based on a population of patients
treated with myelosuppressive chemotherapy for hem-
atologic malignancies or autologous stem cell trans-
plantation in a German tertiary care center.141320Clinical Success
Clinical success in the model was assumed to be
successful treatment of an IFD and survival of the
patient. Ideally, mortality data would be obtained
from head-to-head clinical studies. However, available
clinical studies have limitations; for example, patients
were treated with random mixtures of antifungal
agents, and antifungal treatment in the DD strategy
was delayed based on study criteria, which may have
affected mortality. Furthermore, comparative clinical
studies of patients receiving empirical therapy versus
DD therapy reported very high overall survival rates
for both arms,8,9,11 which made it difﬁcult to estimate
the true impact of the treatment strategy on survival.
As a result of these limitations, data from epidemio-
logic studies were obtained. Mortality was estimated
from observations derived from neutropenic patients
with hematologic malignancies or who were receiving
autologous stem cell transplantation in a German
tertiary care center between 2002 and 2006; overall
mortality was 10.7% (95% CI, 9–13) and IFD-related
mortality was 28.6% (95% CI, 19–39).13 Assuming
that patients without an IFD would not die because of
this disease, we assumed that patients with an IFD
would have an increase in mortality of 28.6%. Given
this assumption, the overall mortality was adjusted to
be speciﬁc for patients with an IFD (36.2%) and for
patients without an IFD (7.6%). The speciﬁc mortality
values and the calculations are presented in Figures 1B
and 1C and Supplemental Table I (as given in the
online version at http://dx.doi.org/10.1016/j.clinthera.
2015.03.021).
Hahn-Ast et al13 also estimated the impact of using
nonpolyene antifungal agents (deﬁned as voriconazole
and caspofungin) on overall survival. They performed a
multivariate analysis for overall survival in patients with
IFD and reported that the use of these novel antifungal
agents was associated with a signiﬁcant improvement in
overall survival (hazard ratio, 0.589 [95% CI, 0.362–
0.959]; P ¼ 0.033). Using these data, the IFD-related
and non–IFD-related mortality rates were adjusted to be
speciﬁc for patients receiving amphotericin-based agents
and patients on novel antifungal agents (Supplemental
Table I, given in the online version at http://dx.doi.org/
10.1016/j.clinthera.2015.03.021).
Other assumptions made for clinical success and
mortality were that treatment with antifungal agents
beneﬁted only those patients with an IFD. Instances of
IFD identiﬁed by using the DD strategy, but notVolume 37 Number 6
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occur among patients treated with antifungal agents in
the empirical strategy arm; GM-ELISA and PCR tests
were assumed to have a sensitivity of 67.7%15; and
the empirical strategy only identiﬁed 29% to 31% of
the IFD conﬁrmed by using the DD strategy.8,11Adverse Events
Adverse events (AEs) in the model were those
that occurred in Z10% of patients in the empirical
trials16–18 and that were deemed to be most resource
intensive. As recommended by the key opinion leaders
(R. Barnes, R. Herbrecht, O. Morrissey, M. Slavin,
E. Bow, J. Maertens, and C. Cordonnier, personal
communications, October and November 2012), the
AEs were limited to nephrotoxicity, tachycardia, and
hypertension. To normalize the percentages to a com-
mon population, the percentage of patients experienc-
ing AEs during receipt of caspofungin, voriconazole, or
amphotericin B was estimated by applying the absolute
difference in AEs seen between each antifungal agent
and L-AmB within the respective trials to the pooled
AE percentages derived for L-AmB. The proportions of
patients experiencing the AEs associated with each
antifungal agent are presented in Table I.16,18Resource Use and Costs
Health care resources and costs considered in the
model were general health care resources used to
manage each treatment strategy, antifungal treatment
costs, and costs to treat AEs.Table I. Proportion of patients receiving antifungal age
costs of the AEs.
AE
Antifungal
C-AmB Caspofungin
Hypertension* 9.6% 0.6%
Nephrotoxicity† 27.1% 3.2%
Tachycardia* 10.8% 0.6%
C-AmB ¼ conventional amphotericin B; L-AmB ¼ liposomal am
*Hypertension and tachycardia were only reported in the study b
estimated.
†Deﬁned as a doubling of the serum creatinine level or an incre
June 2015General health care resource costs in the model
were estimated by using a micro-costing approach.
Speciﬁcally, resource use for general diagnosis and
treatment within an empirical therapy or DD
strategy was initially estimated from the pub-
lished literature7,8,11,12 and then reviewed by the
key opinion leaders (R. Barnes, O. Morrissey,
M. Slavin, and J. Maertens, personal communica-
tions, November 2012). Patients in the DD strategy
used health care resources in a manner similar
to those treated via the empirical strategy, except
that patients in the DD strategy were also screened
for Aspergillus species until they recovered from
neutropenia. The health care resources, percentages
of patients expected to receive resources, and the
mean number of resources patients were expected
to use during the treatment strategy are presented in
Table II.19
Antifungal agent use for each treatment strategy
was obtained from the speciﬁc product character-
istics14,20–23 and reviewed by the key opinion
leaders (R. Barnes, O. Morrissey, M. Slavin, and
J. Maertens, personal communications, November
2012). Costing of antifungal agents depended on
patient weight. The average patient weight, used to
calculate the average unit cost, was estimated as the
average weight of men and women in England in
2010 (84.6 kg and 71.2 kg, respectively).24 The
model considered treatment from the point of
infection, and antifungal prophylaxis before
initiation of empirical therapy was not included.
Patients treated with the DD strategy were assumednts who experienced adverse events (AEs) and the
Agent
Cost per AE (£)L-AmB Voriconazole
0.6% 0.6% 110.77
12.1% 11.5% 88.12
0.6% 0.6% 165.34
photericin B.
y Walsh et al.1 The difference between C-AmB and L-AmB is
ase of at least 88.4 μmol/L if elevated at baseline.16,18
1321
Table II. General resource use according to treatment strategy and unit costs.
Resource
Proportion of Patients Using
Resource (%)
Mean No. of
Resources Used
Unit Cost (£)DD Empirical DD Empirical
Neutrophil count tests 100.0 100.0 17.9 17.9 3.05
Chest radiograph 83.3 83.3 4.2 4.2 58.57
Blood cultures 98.3 98.3 7.4 11.5 3.05
Urine cultures 73.3 75.0 11.9 3.0 1.26
Nasal, pharyngeal, and rectal swab 100.0 100.0 9.5 9.5 1.26
CT scan 70.0 65.0 1.0 1.0 61.00
Abdominal echography 21.7 8.3 1.0 1.0 50.47
Bronchoscopy 25.0 18.0 1.0 1.0 583.48
Bronchoalveolar lavage 25.0 18.0 1.0 1.0 583.48
Cytomegalovirus PCR 60.0 60.0 14.3 14.3 1.23
Nonfungal molecular tests* 20.0 20.0 14.3 14.3 1.23
Lung biopsy 2.0 2.0 1.0 1.0 646.68
Transbronchial biopsy 4.0 4.0 1.0 1.0 646.68
Skin biopsy 4.0 4.0 1.0 1.0 146.72
Galactomannan antigenemia screening† 100.0 – 7.4 – 3.05
Aspergillus PCR test 100.0 – 4.0 – 1.23
DD ¼ diagnostic-driven; CT ¼ computerized tomography; PCR ¼ polymerase chain reaction.
Costs were obtained from standard UK costing sources.1
*Molecular tests included human herpes virus 6 PCR, herpes PCR, and adenovirus PCR.
†Galactomannan screening costs are provided as a kit of 96 tests. The cost of a single assay is estimated to be £3.05
(ie, £292.80 per kit/96 tests per kit).
Clinical Therapeuticsto receive antifungal prophylaxis with ﬂuco-
nazole 400 mg/d for 18 days.8 Mold-active
antifungal prophylaxis was not administered to
patients in either strategy. Antifungal therapy dos-
ing details, unit costs, and administration costs are
presented in Table III.14,19–23,25
For costing AEs (Table I), the key opinion leaders
outlined typical treatment that would be associated
with each AE (R. Barnes, O. Morrissey, M. Slavin,¼ total cost of DD strategy – total cost of empirical strategyð Þ
number of survivors in DD strategy– number of survivors in empirical strategyð Þand J. Maertens, personal communications, Novem-
ber 2012). Treatment algorithms for each AE are
presented in Supplemental Tables II and III (as given1322in the online version at http://dx.doi.org/10.1016/
j.clinthera.2015.03.021).19,26
Model Calculations
For each treatment strategy, we derived the number
of patients treated with antifungal drug therapy, the
number of diagnosed IFD, the number of deaths, and
costs. The incremental cost per death avoided was
calculated as:Sensitivity Analyses
To test the robustness of model assumptions and
parameters, the effect of changing parameters in bothVolume 37 Number 6
Table III. Distribution of antifungal agents administered in patients who received antifungal therapy, duration
of use, dosing, administration time, and unit costs.
Antifungal
Agent
DD Strategy Empirical Strategy
Dosage Unit Cost (£)
Administration
Time (h)*% Using Duration (d) % Using Duration (d)
C-AmB 2.3 21.0 3.5 21.0 1.0 mg/kg/d 7.76 3.0
Caspofungin NA NA 38.7 28.0 70-mg loading dose on day 1;
maintenance dose of 50 mg
QD
Day 1: 416.78 1.0
Post day
1: 327.67
L-AmB 52.7 23.3 57.8 23.3 3 mg/kg/d 483.45 2.0
Voriconazole 44.9 30.3 NA NA 6 mg/kg every 12 h loading dose
on day 1; maintenance dose
of 4 mg/kg BID on days 2–7;
200 mg oral BID on day 8þ
Day 1: 385.70 1.5 from day
1 to 7Post day
1: 231.42
Post day 7: 78.77
Fluconazole† 100 18.0 NA NA 400 mg QD 1.42 0 (oral agent)
DD ¼ diagnostic-driven; C-AmB ¼ conventional amphotericin B; NA ¼ not applicable; QD ¼ once daily;
L-AmB ¼ liposomal amphotericin B.
Sources include the British National Formulary19 and Summaries of Product Characteristics.14,20–22
*Day ward nurse hourly wage was assumed to be £85.00.25
†Fluconazole was used only as a prophylactic treatment.
R. Barnes et al.1-way and probabilistic sensitivity analyses were
examined. Parameters analyzed in 1-way sensitivity
analyses included the incidence of IFD, overall and
IFD mortality, overall survival hazard ratio, GM-
ELISA/PCR test sensitivity, unit costs and probability
of AEs, percentage of patients receiving each anti-
fungal agent, duration of antifungal therapy, percentage
of patients using each resource, and number of resour-
ces used for each antifungal agent within each strategy.
The effects of varying individual parameters were
examined by using plausible ranges of values from the
literature, 95% CIs, or by varying estimates by 20%.
Sensitivity results for each input were ranked from most
sensitive to least sensitive and were plotted on a tornado
diagram.
In addition to 1-way sensitivity analyses, prob-
abilistic sensitivity analyses (second-order Monte
Carlo simulation) were also performed. The parame-
ters varied in these analyses and were similar to those
in the 1-way sensitivity analyses. We assumed that
parameter estimates followed a γ distribution for
the following parameters: overall survival hazard
ratio, unit costs, duration of antifungal therapy, and
number of resources used for each antifungal agent
within each strategy. A β distribution was assumedJune 2015for the incidence of IFD, overall and IFD mortality,
GM-ELISA/PCR test sensitivity, probability of AEs,
and percentage of patients using each resource.
A Dirichlet distribution was assumed for the percent-
age of patients receiving each antifungal agent within
each strategy. Analyses were run 10,000 times to
capture stability in the results for each relevant
scenario. Scatter plots were developed to represent
uncertainty, and cost-effectiveness acceptability curves
were created.
RESULTS
Baseline Findings
The number of conﬁrmed IFD in the DD strategy
(74 of 1000 at-risk patients) was more than the
number of conﬁrmed IFD in the empirical strategy
(33 of 1000 at-risk patients). However, the DD
strategy was associated with a smaller number of
patients who were given antifungal treatment com-
pared with the empirical strategy (74 of 1000 vs 125
of 1000 at-risk patients, respectively). Survival among
patients in the DD and empirical strategies were
similar: 90.8% and 89.8% of patients, respectively.
Although patients treated according to a DD
strategy versus an empirical strategy incurred greater1323
Table IV. Baseline results of costs and outcomes of diagnostic-driven (DD) and empirical strategies.
Model Outcome DD Approach Empirical Approach
Total costs, £ per patient 1561.29 2301.93
Antifungal treatment costs 799.21 1678.06
Antifungal agent AE costs 0.96 1.34
GM and PCR costs 27.46 0
Other medical costs* 733.66 622.53
No. of patients treated with antifungal drug
therapy (per 1000 patients)
74 125
No. of diagnosed IFD (per 1000 patients) 74 33
No. of deaths (per 1000 patients) 92 102
Probability of survival, % 90.8 89.8
AE ¼ adverse event; GM ¼ galactomannan; PCR ¼ polymerase chain reaction; IFD ¼ invasive fungal disease.
*Higher “other” medical costs were incurred in the DD strategy due to the use of additional health care resources such as
computed tomography scans, abdominal echography, bronchoscopy, and bronchoalveolar lavage.
Clinical Therapeuticscosts due to the use of biomarkers (£27.46 vs £0,
respectively), patients treated by using a DD strategy
incurred lower overall costs (difference of £740.64)
due to the effective use of antifungal agents. As a
result, the DD-based treatment strategy was cost-
saving (ie, costs were less, the strategy prevented more
deaths). The baseline results are presented in Table IV.Sensitivity Analysis
Figure 2 illustrates the sensitivity of the incremental
cost per death avoided for the DD strategy versus the
empirical strategy. Compared with the empirical
strategy, the resulting incremental cost per death
avoided was most sensitive to changes in GM-ELISA
test sensitivity. Speciﬁcally, the DD strategy remained
less costly and more effective in preventing death
when GM-ELISA test sensitivity approached its lower
limit. Results were somewhat sensitive to changes in
the relative increase in the number of patients treated
in the empirical versus DD strategy, incidence of IFD,
and the duration of treatment with L-AmB in the
empirical arm. However, despite changes in these
parameters within their plausible ranges, the DD
strategy was still cost-saving. Changes in all other
parameters did not affect the results (ie, the DD
strategy remained less costly while avoiding more
deaths than the empirical strategy).1324Figure 3 shows the resulting scatter plot of a DD
strategy compared with an empirical strategy. In this
analysis, assuming that the distribution of antifungal
treatment in the different strategies does not change,
the DD strategy was found to be less costly while
preventing more deaths (ie, runs of the model with
results falling within quadrant 4) 90.16% of the time.
The incremental cost per death avoided was £30,000
or less (ie, runs of the model with results falling below
the dotted diagonal line within quadrant 1 and
quadrant 4) 99.24% of the time. Owing to the
possible variability in the hazard ratios for overall
survival for newer antifungal agents, many of the
simulations fell within the second (0.14%) and third
(5.91%) quadrants, where the DD strategy was either
more costly and less effective in preventing death or
less costly but did not prevent enough deaths to be
worth the lower cost.
DISCUSSION
In this analysis, we compared the economic impact of
using a DD strategy with an empirical strategy for the
management of patients with persistent or recurrent
neutropenic fevers at risk of IFD. To the best of our
knowledge, this study is the ﬁrst conducted to evaluate
the economic impact of a DD strategy on the manage-
ment of IFD, including suspected IA. According to the
results of our analysis, we estimated that 41% fewerVolume 37 Number 6
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Duration of treatment with liposomal amphotericin B (3 mg/kg/day)
(empirical arm) (base, 23.33; lower limit, 14.19; upper limit, 32.48)
IFD-related mortality (base, 28.57%; lower limit, 19.00%; upper limit, 39.00%)
Duration of treatment with liposomal amphotericin B (3 mg/kg/day) (DD arm)
(base, 23.33; lower limit, 14.19; upper limit, 32.48)
Duration of treatment with caspofungin (70-mg loading dose on day 1 followed by
50 mg QD) (empirical arm) (base, 28.00; lower limit, 17.02; upper limit, 38.98)
Per-day cost postloading dose of caspofungin (50 mg QD)
(base, £327.67; lower limit, £199.22; upper limit, £456.12)
Per-day cost of liposomal amphotericin B (3 mg/kg/day)
(base, £483.45; lower limit, £293.94; upper limit, £672.96)
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Figure 2. One-way sensitivity analysis: effect of parameter variation on the incremental cost per death
avoided for a diagnostic-driven (DD) strategy versus an empirical strategy.
GM ¼ galactomannan; IFD ¼ invasive fungal disease; QD ¼ once daily.
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Figure 3. Results of probabilistic sensitivity analysis: incremental cost per death avoided scatter plot of a
diagnostic-driven strategy versus an empirical strategy. The dotted diagonal line represents an
incremental cost per death avoided of £30,000.
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Clinical Therapeuticspatients would be treated with antifungal agents in a
DD strategy compared with an empirical strategy. As
a result, we were able to avoid more AEs caused by
antifungal treatment in already immunocompromised
patients. In addition, survival was found to be similar
for both the DD and empirical strategies and was
consistent with survival rates reported in published
clinical studies,8,9,12 despite the fact that survival data
were derived from a retrospective medical record
extraction study.13
Overall, given the reduced use of antifungal agents,
the total cost of the DD strategy was reportedly lower
than that of the empirical strategy, despite the addi-
tional costs of GM-ELISA and/or Aspergillus species
PCR testing. The costs of GM-ELISA and PCR testing
were more than offset by lower antifungal treatment
costs as a result of more targeted therapy. The ﬁndings
of this analysis suggest that the DD strategy may be
cost-saving for patients who are neutropenic and have
persistent or recurrent unexplained fevers.
One key factor of this analysis will affect the
overall savings that may be experienced by a given
center; that is, the incidence of IFD that occurs within
the center’s population. This incidence varies not only
between centers due to the environment but also
depending on the case-mix of the patients within any
given center. High-risk patients will have a greater risk
of IFD than lower risk patients. The incidence
assumed within this study was derived from a pop-
ulation of patients treated with myelosuppressive
chemotherapy or autologous stem cell transplantation
for hematologic malignancies in a German tertiary
care center.13 Other centers that treat a greater
proportion of high-risk patients may derive even
greater cost savings from a DD strategy.
Another limitation of this analysis is the exclusion
of prophylaxis with the azole posaconazole. Prophy-
laxis with posaconazole could inﬂuence treatment
options and cost savings for patients at high risk of
IFD but was not considered in this model because the
data to support the outcomes were not available.
An important limitation of this analysis is that
patients who are at risk for fungal disease are a
heterogeneous population. These patients have differ-
ent underlying conditions that result in large varia-
bility in overall mortality rates. As a result, outcomes
of the analyses may vary greatly between patient
subpopulations. However, sensitivity analyses found
that overall mortality was not a large driver of costs.1326This is in keeping with overall survival being relatively
high, as was also seen in the clinical trials of the DD
strategy.8,9,11,12
Another limitation of this analysis is that the incidence,
survival, and efﬁcacy data were not obtained from a single
head-to-head clinical trial but were instead obtained from
a retrospective cohort study of patients treated with
myelosuppressive chemotherapy or autologous stem cell
transplantation for hematologic malignancies in a German
tertiary care center.13 A number of clinical studies have
assessed the outcomes of the DD and empirical
strategies.7–12 However, it is difﬁcult to draw conclusions
about the potential economic impact of the ideal applica-
tion of these 2 strategies because heterogeneous treatment
regimens and DD strategies were used in the clinical
studies. In addition, in 1 study, a delay in the use of
antifungal agents within the DD strategy occurred due to
study inclusion criteria, and this delay may have affected
mortality rates.8 The timing of the implementation of
a DD therapy strategy is important because it may
determine how effective the strategy will be in providing
early treatment compared with an empirical strategy.
A major limitation of the present study was the
assumption that the use of a DD strategy would detect
IFD, such that treatment for these diseases could occur
just as early as empirical treatment. Because DD
strategy studies were administered with the criterion
that patients must be neutropenic for at least 4 to
5 days, it is unknown whether clinical outcomes for a
DD strategy when IFD is identiﬁed earlier differ from
those of a DD strategy when an IFD is identiﬁed later.
Additional clinical studies will be important to fully
understand the impact of this limitation and whether
earlier treatment of IFD improves outcomes.
Overall, untreated IA is associated with high mortal-
ity rates.27 As a result, use of a broad empirical strategy
has historically been the standard treatment approach
to attempt to alleviate physicians’ concerns that some
cases of IFD may be missed. Our analysis found that
the DD strategy with targeted treatment may be
considered a cost-saving alternative to the empirical
strategy, while maintaining a similar overall survival
rate. Future head-to-head studies collecting economic
data will be important to conﬁrm these analyses.
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Supplemental Table I. Mortality rates.
Parameter Model Estimate (%)
Overall mortality 10.7
Mortality with an IFD* 36.2
Mortality without an IFD* 7.6
Mortality if treated with amphotericin agent†
Mortality with an IFD 40.4
Mortality without an IFD 7.6
Mortality if treated with novel antifungal agent†
Mortality with an IFD 16.6
Mortality without an IFD 7.6
IFD ¼ invasive fungal disease.
*Mortality with and without an IFD were estimated as overall mortality ¼ incidence of IFD  (X þ increased risk of IFD
mortality) þ percentage of patients without IFD  X, where X is the mortality of patients without IFD. This calculation
became 10.7% ¼ 10.9% (X þ 28.6%) þ (100.0% – 10.9%)  X; thus X ¼ 7.6%. IFD-related mortality was calculated as 36.2%
(7.6% þ 28.6%).
†Mortality for patients treated with an amphotericin agent is estimated as mortality ¼ percentage of patients on novel
antifungal agents  (X  [1 – 0.589]) þ percentage of patients on amphotericin-based agents  X, where X is the mortality
of patients on amphotericin-based agents. Within Hahn-Ast et al,13 15 patients (10 patients on caspofungin and 5 patients
on voriconazole) of 84 patients were on novel antifungal agents. Non–IFD-related mortality for patients on amphotericin-
based agents and novel antifungal agents was assumed to be the same as the overall mortality without IFD. IFD-related
mortality for patients on amphotericin-based agents was 36.2% ¼ (15/84) (1 – 0.589)  X þ ((84 – 15)/84)  X; thus
X ¼ 40.4%. IFD-related mortality for novel agents was calculated as 16.6% (40.4%  [1 – 0.589]).
R. Barnes et al.Supplemental Table II. Adverse event–related resource use.*
Adverse Event Resource Use
Hypertension Treatment is assumed to include nurse monitoring, verapamil, antihypertensive therapy, and
dialysis
Nephrotoxicity Treatment is assumed to include NaCl infusion prophylaxis, daily electrolytes, abdominal
ultrasound, and daily urine collection
Tachycardia Treatment is assumed to include nurse monitoring and ECG
NaCl ¼ sodium chloride.
*Resource uses for treating AEs were provided by clinicians via ECODE Model Resource Use Questionnaire.June 2015 1328.e1
Supplemental Table III. Adverse event (AE)-related costs.
AE
Unit
Cost (£) % Using
No. of
Resources Source/Assumptions
Hypertension 110.77 Cost of this AE was estimated by using the average
number of resources identiﬁed (listed below) by
the KOLs and weighted by the number of KOLs
identifying each resource below
Hypertension: AE
components
Nursing monitoring 164.00 66.7 2.0 Per hour of patient contact We assumed 2
additional hours of monitoring time
Verapamil 1.73 33.3 1.0 British National Formulary18
Antihypertensive
therapy
1.03 33.3 1.0 British National Formulary18
Dialysis 1% 1.56 33.3 1.0 Hospital hemodialysis or ﬁltration, with access
via hemodialysis catheter, for patients aged
Z19 years. This is the average of elective
inpatient, elective inpatient excess bed days,
nonelective inpatient (long stay), nonelective
inpatient (long stay) excess bed days, and
nonelective inpatient (short stay)
Nephrotoxicity 88.12 Cost of this AE was estimated by using the average
number of resources identiﬁed (listed below) by
the KOLs and weighted by the number of KOLs
identifying each resource below
Nephrotoxicity: AE
components
NaCl infusion
prophylaxis
85.40 33.3 1.0 NaCl infusion 1 l (1000 ml)
Daily electrolytes 89.56 33.3 1.0 Direct access: pathology services phlebotomy
(electrolytes)
Abdominal
ultrasound
51.27 33.3 1.0 Ultrasound scan o20 min
Daily urine
collection
38.13 33.3 1.0 Daily urine collection
Tachycardia 165.34 Cost of this AE was estimated by using the average
number of resources identiﬁed (listed below) by
the KOLs and weighted by the number of KOLs
identifying each resource below
Tachycardia: AE
components
Nurse monitoring 164.00 66.7 2.0 Per hour of patient contact. We assumed 2
additional hours of monitoring time
ECG 84.01 66.7 2.0 Diagnostic imaging outpatient
KOL ¼ key opinion leader; NaCl ¼ sodium chloride.
Sources: Department of Health26 and the British National Formulary.18
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